OncoMatch/Clinical Trials/NCT03667170
KN035 for dMMR/MSI-H Advanced Solid Tumors
Is NCT03667170 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies KN035 for solid tumor.
Treatment: KN035 — In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy. For colorectal cancer participants, who are required to have been previously treated with standard therapies , other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor or agonist
Has received prior therapy with an immune check point agonist/inhibitor.
Cannot have received: investigational agent/device
Exception: if within 4 weeks of first dose
Currently participated in a study of an investigational agent and received trial treatment, or used an investigational device within 4 weeks of the first dose of medication in this study.
Cannot have received: anti-tumor treatment
Exception: if within 2 weeks prior to first dose
Patients who have had specific anti-tumor treatment within 2 weeks prior to the first dose of study.
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate hematologic and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify